November 2025 SCRI Release Copied

SCRI Trials and Trial Regimen Updates

The following updates were completed between October 22 – November 13, 2025. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.

For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.

New Builds Completed

Study Number	Notes for New Build
24164	USOR 24164 CML 29 Phase 3 Part A Bosutinib Q28D – v1.4 05FEB2024 USOR 24164 CML 29 Phase 3 Part A Olverembatinib Q28D – v1.4 05FEB2024 USOR 24164 CML 29 Phase 3 Part B Olverembatinib Q28D – v1.4 05FEB2024
24257	USOR 24257 GU 265 Phase 2 Part A Dato-DXd + Carboplatin Q21D – v1.0 16APR2025 USOR 24257 GU 265 Phase 2 Part A Dato-DXd + Cisplatin Q21D – v1.0 16APR2025 USOR 24257 GU 265 Phase 3 Part B Gemcitabine + Carboplatin Q21D – v1.0 16APR2025 USOR 24257 GU 265 Phase 3 Part B Gemcitabine + Cisplatin Q21D – v1.0 16APR2025
24314	USOR 24314 LUN 602 Phase 2 Stage 1 Osimertinib Q21D – v1.0 14MAR2025 USOR 24314 LUN 602 Phase 2 Stage 1 Pre-randomization Osimertinib (1 cycle) Q21D – v1.0 14MAR2025 USOR 24314 LUN 602 Phase 2 Stage 1 Telisotuzumab adizutecan + Osimertinib Q21D – v1.0 14MAR2025
24264	USOR 24264 RM 921 Phase 1/2 Part 2 Arm 2B AU-007 + Aldesleukin Q56D – 24JUL2025 USOR 24264 RM 921 Phase 1/2 Part 3 AU-007 + Aldesleukin + Avelumab Q56D – 24JUL2025 USOR 24264 RM 921 Phase 1/2 Part 4 AU-007 + Aldesleukin + Nivolumab Q56D – 24JUL2025
24279	USOR 24279 MULTI 101 Phase 1b ZL-1310 Q21D – v2.0 18FEB2025
23265	USOR 23265 LUN 588 Phase 2 WSD0922-FU Q21D (C1-7) – v2.0 11DEC2024 USOR 23265 LUN 588 Phase 2 WSD0922-FU Q42D (C8+) – v2.0 11DEC2024
24248	USOR 24248 MM 194 Substudy 1 Phase 1 Etentamig + Daratumumab + Lenalidomide + Dexamethasone Q28D – v3.0 31MAR2025 USOR 24248 MM 194 Substudy 2 Phase 1 Etentamig Q28D – v3.0 31MAR2025 USOR 24248 MM 194 Substudy 3 Phase 1 Etentamig + Carfilzomib + Dexamethasone Q28D – v3.0 31MAR2025 USOR 24248 MM 194 Substudy 4 Phase 1 Etentamig + Lenalidomide Q28D – v3.0 31MAR2025
24046	USOR 24046 GYN 146 Phase 3 Arm A T-DXd + Rilvegostomig Q21D – v2.0 27NOV2024 USOR 24046 GYN 146 Phase 3 Arm B T-DXd + Pembrolizumab Q21D – v2.0 27NOV2024 USOR 24046 GYN 146 Phase 3 Arm C Maintenance Pembrolizumab Q42D – v2.0 27NOV2024 USOR 24046 GYN 146 Phase 3 Arm C Pembrolizumab + Docetaxel + Carboplatin Q21D – v2.0 27NOV2024 USOR 24046 GYN 146 Phase 3 Arm C Pembrolizumab + Paclitaxel + Carboplatin Q21D – v2.0 27NOV2024
24152	USOR 24152 GI 383 Phase 3 Arm A T-DXd + Rilvegostomig + 5-FU Q21D – v2.0 17FEB2025 USOR 24152 GI 383 Phase 3 Arm A T-DXd + Rilvegostomig + Capecitabine Q21D – v2.0 17FEB2025 USOR 24152 GI 383 Phase 3 Arm B Pembrolizumab + Trastuzumab + CAPOX Q21D – v2.0 17FEB20253 USOR 24152 GI 383 Phase 3 Arm B Pembrolizumab + Trastuzumab + FP Q21D – v2.0 17FEB2025 USOR 24152 GI 383 Phase 3 Arm C Rilvegostomig + Trastuzumab + CAPOX Q21D – v2.0 17FEB2025 USOR 24152 GI 383 Phase 3 Arm C Rilvegostomig + Trastuzumab + FP Q21D – v2.0 17FEB2025
24041	USOR 24041 LUN 570 Phase 3 Adjuvant Pembrolizumab Q42D USOR 24041 LUN 570 Phase 3 Adjuvant V940 or Placebo + Pembrolizumab Q42D USOR 24041 LUN 570 Phase 3 Neoadjuvant Pembrolizumab + Gemcitabine + Carboplatin Q21D USOR 24041 LUN 570 Phase 3 Neoadjuvant Pembrolizumab + Gemcitabine + Cisplatin Q21D USOR 24041 LUN 570 Phase 3 Neoadjuvant Pembrolizumab + Paclitaxel + Carboplatin Q21D USOR 24041 LUN 570 Phase 3 Neoadjuvant Pembrolizumab + Paclitaxel + Cisplatin Q21D USOR 24041 LUN 570 Phase 3 Neoadjuvant Pembrolizumab + Pemetrexed + Carboplatin Q21D USOR 24041 LUN 570 Phase 3 Neoadjuvant Pembrolizumab + Pemetrexed + Cisplatin Q21D
24298	USOR 24298 LUN 598 Phase 1b/2 Part 1 BNT324 + BNT327 Q21D – v3.0 04FEB2025
24292	USOR 24292 GU 267 Phase 3 Pasritamig or Placebo Q42D (Cycle 2+) – 22APR2025 USOR 24292 GU 267 Phase 3 Pasritamig or Placebo Q56D (Cycle 1) – 22APR2025
25033	25033 GU 275 Phase 3 Cabozantinib + Casdatifan or Placebo Q28D v2.0 30May2025
25092	USOR 25092 MM 207 Phase 3 Arm A Belantamab Mafodotin + Lenalidomide + Dexamethasone Q56D – 12NOV2024 USOR 25092 MM 207 Phase 3 Arm A Belantamab Mafodotin + Lenalidomide + Dexamethasone Q84D – 12NOV2024 USOR 25092 MM 207 Phase 3 Arm B Daratumumab + Lenalidomide + Dexamethasone Q28D – 12NOV2024
25143	USOR 25143 LYM 271 Phase 3 Arm A Cyclophosphamide + Fludarabine D-5,-4,-3 – v1.0 24JUL2025 USOR 25143 LYM 271 Phase 3 Arm A Ronde-cel D0 – v1.0 24JUL2025 USOR 25143 LYM 271 Phase 3 Arm B Lymphodepleting Chemotherapy fb Investigator’s Choice CD19 CAR T (Placeholder) – v1.0 24JUL2025 USOR 25143 LYM 271 Phase 3 Bridging Therapy (Placeholder) – v1.0 24JUL2025
25028	USOR 25028 GU 274 Phase 3 Mevrometostat or Placebo + Enzalutamide Q28D – 16JUN2025

Updated Reference Information

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
21353	PAv10: 06 Jun 2025	Regimen comments; prophylaxis	Update drug; dose/form, name, premedication, instructions. New Arms
22067	PM 9.0; 08 Oct 2025	N/A	Update drug; instructions
23047	Version 3.0; 06 June 2025	N/A	Added: Drug Update drug; instructions
23182	PA4: 19 Nov 2024	Regimen comments; Admin, Prophylaxis	Update drug; Instructions, Admin/Pre, Dose/Form, Premedication, Frequency
23240	PA V6, 11APRIL2025	Regimen Comments; Admin	Update Drug; Admin/Prep, Instructions
23304	PM v5.0; 26 Sept 2025	N/A	Update Drug; Instructions
24007	PM v4.0; 05 August 2025	N/A	Update Drug; Dose/Form, Instructions
24099	PA v5.0; 28 July 2025	Regimen Comments; Admin	Update Drug; Dose/Form, Instructions, Premedication
24164	PM v3.0; 29 Sept 2025	N/A	Update Drug; Dose/Form
24189	PM v4.0; 10 Sept 2025	N/A	Update Drug; Instructions
24211	PA v9.0: 18 Jul 2025	N/A	Update Drug; Instructions, Procurement. New Arm(S)
24288	Version 3.0; 30 June 2025	Regimen comments; prophylaxis	Update Drug; Admin Prep, Premedication
24306	PA3; 14 Aug 2025	Regimen Comments; Admin, Prophylaxis, premedication	Update Drug; Premedication, procurement
23166	Version 9.0, 16APR2025	N/A	New Regimen
24046	PM v4.0; 01 October 2025	N/A	Update Drug; Instructions